isoniazid has been researched along with Urinary Bladder Neoplasms in 53 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We analyzed the influence of the tuberculostatic agent isoniazid on the incidence and severity of adverse effects of intravesical bacillus Calmette-Guerin (BCG) therapy in patients with superficial bladder cancer." | 9.08 | Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. ( Brausi, M; de Balincourt, C; Höltl, W; Sylvester, R; van der Meijden, AP; Vegt, PD, 1997) |
| "We report a case of sepsis from Mycobacterium bovis Bacillus Calmette-Guérin (BCG) with low-level isoniazid resistance following intravesical treatment for bladder cancer." | 7.77 | Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer. ( Carr, D; Farnsworth, RH; Goldberg, H; Jelfs, P; Jones, P; Sintchenko, V; Taylor, PC; Watts, MR; Whelan, CM, 2011) |
| "To determine the effects of isoniazid (isonicotinic acid hydrazide), used to reduce the serious side-effects of immunotherapy of superficial bladder cancer with bacille Calmette-Guérin (BCG), on the proliferation and constitutive BCG-induced synthesis of interleukins 6 (IL6) and 8 (IL8) in human bladder cancer cells cultured in vitro." | 7.69 | Effects of isoniazid on the proliferation and cytokine production of bladder cancer cells in vitro induced by bacille Calmette-Guérin. ( Bevers, RF; de Boer, EC; Kurth, KH; Schamhart, DH, 1997) |
| "The use of bacillus Calmette-Guérin in the treatment of transitional cell cancer of the bladder has caused concern because of its associated adverse effects." | 6.69 | The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer. ( Al Khalifa, M; Callaghan, P; Colleen, S; Duchek, M; Elfving, P; Eriksson, R; Hagberg, G; Hellsten, S; Månsson, W; Nelson, CE; Nyberg, G; Olsson, R; Rademark, C, 2000) |
| "Isoniazid is a commonly and widely used component of the various treatment regimens." | 6.47 | Isoniazid resistance among Bacillus Calmette Guerin strains: implications on bladder cancer immunotherapy related infections. ( Farber, BF; Malhotra, P, 2011) |
| "In patients with intermediate- and high-risk stage Ta and T1 urothelial bladder cancer, intravesical BCG with or without INH is superior to intravesical epirubicin not only for time to first recurrence but also for time to distant metastases, overall survival, and disease-specific survival." | 5.14 | Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk ( Brausi, MA; Calais Da Silva, F; de Reijke, TM; Gorlia, T; Hoeltl, W; Kirkali, Z; Kirkels, WJ; Powell, PH; Prescott, S; Sylvester, RJ; van de Beek, C, 2010) |
| "After transurethral resection, we compared the efficacy and side effects of weekly intravesical instillations of epirubicin, bacillus Calmette-Guerin (BCG), and BCG plus isoniazid during a 6-week interval followed by 3 weekly maintenance instillations at months 3, 6, 12, 18, 24, 30 and 36 in patients with intermediate and high risk Ta, T1 bladder cancer." | 5.09 | Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-uri ( Brausi, M; de Balincourt, C; Kirkels, W; Sylvester, R; van der Meijden, AP; Zambon, V, 2001) |
| "We analyzed the influence of the tuberculostatic agent isoniazid on the incidence and severity of adverse effects of intravesical bacillus Calmette-Guerin (BCG) therapy in patients with superficial bladder cancer." | 5.08 | Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. ( Brausi, M; de Balincourt, C; Höltl, W; Sylvester, R; van der Meijden, AP; Vegt, PD, 1997) |
| "We report a case of sepsis from Mycobacterium bovis Bacillus Calmette-Guérin (BCG) with low-level isoniazid resistance following intravesical treatment for bladder cancer." | 3.77 | Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer. ( Carr, D; Farnsworth, RH; Goldberg, H; Jelfs, P; Jones, P; Sintchenko, V; Taylor, PC; Watts, MR; Whelan, CM, 2011) |
| "CYP1A2, CYP2D6 and N-acetyltransferase activities were estimated in 100 patients with bladder cancer and 84 control subjects from measurements of theophylline, metoprolol and isoniazid and their metabolites in urine, respectively." | 3.69 | CYP1A2 activity as a risk factor for bladder cancer. ( Jang, IJ; Kim, SW; Lee, KH; Lee, SH; Lee, SW; Oh, SJ; Shin, SG; Yim, DS, 1994) |
| "The activity of urinary N-acetylamino-transferase was determined by high-performance liquid chromatographic assay of acetylisoniazid and isoniazid after administration of isoniazid to healthy Japanese male and bladder cancer patients in Japan." | 3.69 | N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients. ( Hanaoka, T; Hashida, C; Ishizu, S; Maeda, K; Ohishi, Y, 1995) |
| "To determine the effects of isoniazid (isonicotinic acid hydrazide), used to reduce the serious side-effects of immunotherapy of superficial bladder cancer with bacille Calmette-Guérin (BCG), on the proliferation and constitutive BCG-induced synthesis of interleukins 6 (IL6) and 8 (IL8) in human bladder cancer cells cultured in vitro." | 3.69 | Effects of isoniazid on the proliferation and cytokine production of bladder cancer cells in vitro induced by bacille Calmette-Guérin. ( Bevers, RF; de Boer, EC; Kurth, KH; Schamhart, DH, 1997) |
| "At present, isoniazid (INH) is being used prophylactically to reduce the side effects of intravesical BCG therapy for superficial bladder cancer, although it is not clear whether or not this reduces the antitumor efficacy of BCG." | 3.68 | Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. ( de Boer, EC; de Jong, WH; Debruyne, FM; Ruitenberg, EJ; Steerenberg, PA; van der Meijden, AP; van Klingeren, B, 1992) |
| "In 23 patients affected by urinary bladder cancer and 22 healthy volunteers, acetylation phenotype was determined in urine, using the Eidus technique involving isoniazid." | 3.67 | [Acetylation phenotype in patients with cancer of the bladder. Preliminary report]. ( Jeromin, L; Krajewska, B; Polakowski, P; Skretowicz, J; Szymańska, J; Zasada, M, 1988) |
| "The use of bacillus Calmette-Guérin in the treatment of transitional cell cancer of the bladder has caused concern because of its associated adverse effects." | 2.69 | The effect of isoniazid on BCG-induced toxicity in patients with superficial bladder cancer. ( Al Khalifa, M; Callaghan, P; Colleen, S; Duchek, M; Elfving, P; Eriksson, R; Hagberg, G; Hellsten, S; Månsson, W; Nelson, CE; Nyberg, G; Olsson, R; Rademark, C, 2000) |
| "Isoniazid is a commonly and widely used component of the various treatment regimens." | 2.47 | Isoniazid resistance among Bacillus Calmette Guerin strains: implications on bladder cancer immunotherapy related infections. ( Farber, BF; Malhotra, P, 2011) |
| "A 47-year-old man with bladder cancer was treated surgically and received BCG intravesical therapy." | 1.56 | BCGitis of the wrist after intravesical BCG therapy: A case report. ( Berthier, C; Lellouch, AG; Lupon, E; Mansat, P; Martin-Blondel, G; Pollon, T, 2020) |
| "The dosage of bisoprolol was changed to 3." | 1.36 | [Urinary bladder tuberculosis and Bacillus Calmette-Guérin instillation: reduced efficacy of bisoprolol in hypertension]. ( Drechsler, A; Kirch, W, 2010) |
| "There was no recurrence of bladder cancer or balanoposthitis for 15 months and to date." | 1.33 | Granulomatous balanoposthitis after intravesical Bacillus-Calmette-Guerin instillation therapy. ( Akio, H; Kenichi, M; Yoshinori, H; Yusuke, H, 2006) |
| "Cystitis was the most common side effect, being seen to some degree in all patients, although only forcing cessation of BCG therapy in two patients." | 1.30 | Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment. ( Patel, A; Paterson, DL, 1998) |
| " All the symptoms resolved under isoniazid therapy in a dosage of 300 mg/day for three months." | 1.30 | Refractory arthropathy after intravesical bacillus Calmette-Guérin therapy. Usefulness of isoniazide. ( Maillefert, JF; Michel, F; Milas, L; Piroth, C; Tavernier, C; Wautot, A, 1999) |
| "In a population-based study of 2982 bladder cancer patients and 5782 population controls from 10 geographical areas of the US, no excess risk was associated with medications used for tuberculosis treatment or prophylaxis (relative risk (RR) = 0." | 1.27 | Tuberculosis chemotherapy and risk of bladder cancer. ( Fraumeni, JF; Hartge, P; Hoover, RN; Kantor, AF, 1985) |
| "National Cancer Institute and two Federal Agencies, seven drugs were listed." | 1.26 | Epidemiological studies of medically used drugs. ( Clemmesen, J; Hjalgrim-Jensen, S, 1980) |
| "2 59% of controls and 70% of bladder cancer patients were phenotypically 'slow' acetylators." | 1.26 | N-acetylation phenotype in bladder cancer. ( Adams, PC; Clothier, A; Mucklow, JC; Rawlins, MD; Woodhouse, KW, 1982) |
| "One hundred and forty-two cases of bladder cancer and 48 cases of renal cancer were found in the follow-up of a 1963 census population." | 1.26 | Urinary tract cancer and isoniazid. ( Comstock, GW; Glassroth, JL; Snider, DE, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (32.08) | 18.7374 |
| 1990's | 12 (22.64) | 18.2507 |
| 2000's | 7 (13.21) | 29.6817 |
| 2010's | 12 (22.64) | 24.3611 |
| 2020's | 5 (9.43) | 2.80 |
| Authors | Studies |
|---|---|
| Shibutani, K | 1 |
| Ishikawa, K | 1 |
| Mori, N | 1 |
| Lupon, E | 1 |
| Martin-Blondel, G | 1 |
| Pollon, T | 1 |
| Berthier, C | 1 |
| Lellouch, AG | 1 |
| Mansat, P | 1 |
| Tamzali, Y | 1 |
| Jamme, M | 1 |
| Bottet, F | 1 |
| Gauthe, M | 1 |
| Rondeau, E | 1 |
| Pialoux, G | 1 |
| Calin, R | 1 |
| Ducours, M | 1 |
| Desclaux, A | 1 |
| Dutronc, H | 1 |
| Dauchy, FA | 1 |
| Abi-Chahla, ML | 1 |
| Pointillart, V | 1 |
| Wirth, G | 1 |
| Gálvez-López, R | 1 |
| Ruiz-Carazo, E | 1 |
| Láinez-Ramos-Bossini, AJ | 1 |
| García Salguero, AJ | 1 |
| Pérez-García, MC | 1 |
| Rabadán-Caravaca, M | 1 |
| Sampaio, PCM | 1 |
| Lira, YG | 1 |
| Ribeiro, HYU | 1 |
| de Paula Moreira, F | 1 |
| Gadelha, MSM | 1 |
| da Cruz, SFS | 1 |
| Nimmo, A | 1 |
| Gray, A | 1 |
| Patel, A | 2 |
| MacKenzie, J | 1 |
| Fairbairn, I | 1 |
| Selinski, S | 1 |
| Blaszkewicz, M | 1 |
| Ickstadt, K | 1 |
| Hengstler, JG | 1 |
| Golka, K | 1 |
| Rispler, DT | 1 |
| Stirton, JW | 1 |
| Gilde, AK | 1 |
| Kane, KR | 1 |
| Zhuo, C | 1 |
| Li, X | 1 |
| Zhuang, H | 1 |
| Tian, S | 1 |
| Cui, H | 1 |
| Jiang, R | 1 |
| Liu, C | 1 |
| Tao, R | 1 |
| Lin, X | 1 |
| Sylvester, RJ | 1 |
| Brausi, MA | 1 |
| Kirkels, WJ | 1 |
| Hoeltl, W | 1 |
| Calais Da Silva, F | 1 |
| Powell, PH | 1 |
| Prescott, S | 1 |
| Kirkali, Z | 1 |
| van de Beek, C | 1 |
| Gorlia, T | 1 |
| de Reijke, TM | 1 |
| Tijink, BM | 1 |
| de Bree, R | 1 |
| Drechsler, A | 1 |
| Kirch, W | 1 |
| Watts, MR | 1 |
| Taylor, PC | 1 |
| Sintchenko, V | 1 |
| Whelan, CM | 1 |
| Farnsworth, RH | 1 |
| Jones, P | 1 |
| Jelfs, P | 1 |
| Carr, D | 1 |
| Goldberg, H | 1 |
| Arend, SM | 1 |
| van Soolingen, D | 1 |
| Maundrell, J | 1 |
| Fletcher, S | 1 |
| Roberts, P | 1 |
| Stein, A | 1 |
| Lambie, M | 1 |
| Malhotra, P | 1 |
| Farber, BF | 1 |
| Navascués, A | 1 |
| Gil-Setas, A | 1 |
| Tordoya, IJ | 1 |
| Jiménez-Pajares, MS | 1 |
| MANNION, RA | 1 |
| COTTRELL, TL | 1 |
| LLOYD, FA | 1 |
| Van Outryve, SM | 1 |
| Francque, SM | 1 |
| Gentens, PA | 1 |
| De Pauw, FF | 1 |
| Van den Bogaert, E | 1 |
| Van Marck, EA | 1 |
| Pelckmans, PA | 1 |
| Michielsen, PP | 1 |
| Shigehara, K | 1 |
| Kobori, Y | 1 |
| Amano, T | 1 |
| Takemae, K | 1 |
| Yusuke, H | 1 |
| Yoshinori, H | 1 |
| Kenichi, M | 1 |
| Akio, H | 1 |
| Weber, WW | 1 |
| Hein, DW | 1 |
| Litwin, A | 1 |
| Lower, GM | 1 |
| Clemmesen, J | 1 |
| Hjalgrim-Jensen, S | 1 |
| Woodhouse, KW | 1 |
| Adams, PC | 1 |
| Clothier, A | 1 |
| Mucklow, JC | 1 |
| Rawlins, MD | 1 |
| Lee, SW | 1 |
| Jang, IJ | 1 |
| Shin, SG | 1 |
| Lee, KH | 1 |
| Yim, DS | 1 |
| Kim, SW | 1 |
| Oh, SJ | 1 |
| Lee, SH | 1 |
| Stassar, MJ | 1 |
| Vegt, PD | 2 |
| Steerenberg, PA | 2 |
| van der Meijden, AP | 4 |
| Meiring, HD | 1 |
| Dessens-Kroon, M | 1 |
| Geertzen, HG | 1 |
| den Otter, W | 1 |
| Varoqua, S | 1 |
| Lin-Greenberg, A | 1 |
| Brown, M | 1 |
| Ishizu, S | 1 |
| Hashida, C | 1 |
| Hanaoka, T | 1 |
| Maeda, K | 1 |
| Ohishi, Y | 1 |
| Sylvester, R | 2 |
| Brausi, M | 2 |
| Höltl, W | 1 |
| de Balincourt, C | 2 |
| Bevers, RF | 1 |
| de Boer, EC | 2 |
| Kurth, KH | 1 |
| Schamhart, DH | 1 |
| Hurle, R | 1 |
| Losa, A | 1 |
| Ranieri, A | 1 |
| Lembo, A | 1 |
| Paterson, DL | 1 |
| Griggs, H | 1 |
| Cammarata, SK | 1 |
| Milas, L | 1 |
| Maillefert, JF | 1 |
| Michel, F | 1 |
| Piroth, C | 1 |
| Wautot, A | 1 |
| Tavernier, C | 1 |
| Aljada, IS | 1 |
| Crane, JK | 1 |
| Corriere, N | 1 |
| Wagle, DG | 1 |
| Amsterdam, D | 1 |
| Al Khalifa, M | 1 |
| Elfving, P | 1 |
| Månsson, W | 1 |
| Colleen, S | 1 |
| Hellsten, S | 1 |
| Duchek, M | 1 |
| Nyberg, G | 1 |
| Callaghan, P | 1 |
| Rademark, C | 1 |
| Eriksson, R | 1 |
| Olsson, R | 1 |
| Hagberg, G | 1 |
| Nelson, CE | 1 |
| Rischmann, P | 1 |
| Desgrandchamps, F | 1 |
| Malavaud, B | 1 |
| Chopin, DK | 1 |
| Zambon, V | 1 |
| Kirkels, W | 1 |
| Miller, CT | 2 |
| Neutel, CI | 1 |
| Nair, RC | 1 |
| Marrett, LD | 1 |
| Last, JM | 1 |
| Collins, WE | 1 |
| Glassroth, JL | 1 |
| Snider, DE | 1 |
| Comstock, GW | 1 |
| van Klingeren, B | 1 |
| de Jong, WH | 1 |
| Debruyne, FM | 1 |
| Ruitenberg, EJ | 1 |
| Steg, A | 1 |
| Leleu, C | 1 |
| Debré, B | 1 |
| Boccon-Gibod, L | 1 |
| Sicard, D | 1 |
| Skretowicz, J | 1 |
| Polakowski, P | 1 |
| Jeromin, L | 1 |
| Zasada, M | 1 |
| Szymańska, J | 1 |
| Krajewska, B | 1 |
| Brown, SL | 1 |
| Lamm, DL | 1 |
| Stogdill, VD | 1 |
| Stogdill, BJ | 1 |
| Crispen, RG | 1 |
| Anderson, TW | 1 |
| Kantor, AF | 1 |
| Hartge, P | 1 |
| Hoover, RN | 1 |
| Fraumeni, JF | 1 |
| Brown, RR | 1 |
| Rose, DP | 1 |
| Price, JM | 1 |
| Wolf, H | 1 |
| Grasso, P | 1 |
| Crampton, RF | 1 |
| Boyland, E | 1 |
| Munn, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms With Prophylactic Pentosan Polysulphate in Patients With Non-Muscle-Invasive Bladder Cancer: A Randomized Controlled Trial[NCT03549650] | Phase 2 | 3 participants (Actual) | Interventional | 2019-05-03 | Terminated (stopped due to Given the updated precautions on Elmiron as well as the risk benefit profile, we have decided to terminate the study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for isoniazid and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Mycobacterium bovid infection of total knee arthroplasty after bacille Calmette-Guérin therapy for bladder cancer.
Topics: Administration, Intravesical; Aged; Antitubercular Agents; Arthroplasty, Replacement, Knee; BCG Vacc | 2015 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Isoniazid resistance among Bacillus Calmette Guerin strains: implications on bladder cancer immunotherapy related infections.
Topics: Anti-Bacterial Agents; Carcinoma, Transitional Cell; Dose-Response Relationship, Drug; Drug Resistan | 2011 |
Bacillus Calmette-Guérin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antitubercular Agents; BCG Vaccine; Biop | 2004 |
BCG intravesical instillations: recommendations for side-effects management.
Topics: Administration, Intravesical; Antitubercular Agents; BCG Vaccine; Drug Hypersensitivity; Humans; Iso | 2000 |
The value of the mouse in carcinogenicity testing.
Topics: Animals; Carcinogens; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Epithelium; Ethers, Cycli | 1972 |
The correlation of experimental carcinogenesis and cancer in man.
Topics: Alkylating Agents; Animals; Anthelmintics; Carcinogens; Environmental Exposure; Griseofulvin; Humans | 1969 |
5 trials available for isoniazid and Urinary Bladder Neoplasms
41 other studies available for isoniazid and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Uncommon but Clinically Significant: Bacillus Calmette-Guerin (BCG) Infection of the Urinary Tract and its Impact on Quality of Life.
Topics: Aged; Aged, 80 and over; BCG Vaccine; Ethambutol; Humans; Isoniazid; Male; Mycobacterium bovis; Qual | 2023 |
BCGitis of the wrist after intravesical BCG therapy: A case report.
Topics: Antibiotics, Antitubercular; Arthritis, Infectious; BCG Vaccine; Carpal Bones; Ethambutol; Humans; I | 2020 |
Intravesical BCG instillation as a possible cause of acute and chronic kidney injury.
Topics: Acute Kidney Injury; Administration, Intravesical; Aged; Antitubercular Agents; BCG Vaccine; Ethambu | 2021 |
About three cases of Mycobacterium bovis bone and joint infections after BCG therapy.
Topics: Aged; Aged, 80 and over; Antitubercular Agents; Arthritis, Infectious; BCG Vaccine; Ethambutol; Fata | 2021 |
Miliary tuberculosis secondary to intravesical instillation of Bacillus Calmette-Guérin. Report of two cases.
Topics: Administration, Intravesical; Aged; Antitubercular Agents; BCG Vaccine; Ethambutol; Humans; Isoniazi | 2021 |
Poncet's disease after the intravesical instillation of Bacillus Calmette-Guérin (BCG): a case report.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adrenal Cortex Hormones; Arthritis, Reactive; | 2017 |
Pleural effusion as a late complication of intravesical BCG treatment.
Topics: Aged, 80 and over; Antitubercular Agents; BCG Vaccine; Biopsy; Carcinoma, Transitional Cell; Diagnos | 2018 |
Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
Topics: Alleles; Amino Acid Substitution; Arylamine N-Acetyltransferase; Caffeine; Case-Control Studies; Gen | 2013 |
[Diagnostic image. A man with a swelling under his jaw].
Topics: Aged; BCG Vaccine; Carcinoma; Humans; Isoniazid; Lymph Nodes; Male; Rifampin; Treatment Outcome; Tub | 2009 |
[Urinary bladder tuberculosis and Bacillus Calmette-Guérin instillation: reduced efficacy of bisoprolol in hypertension].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antihypertensive Agents; Antitubercular | 2010 |
Editor's choice: Implications of isoniazid resistance in Mycobacterium bovis Bacillus Calmette-Guérin used for immunotherapy in bladder cancer.
Topics: Administration, Intravesical; Aged; Antitubercular Agents; Bacteremia; Biological Therapy; Drug Resi | 2011 |
Editor's choice: Editorial commentary: Low level INH-resistant BCG: a sheep in wolf's clothing?
Topics: Antitubercular Agents; Biological Therapy; Drug Resistance, Bacterial; Humans; Immunotherapy; Isonia | 2011 |
Mycotic aneurysm of the aorta as a complication of Bacillus Calmette-Guérin instillation.
Topics: Administration, Intravesical; Aged; Aneurysm, Infected; Antibiotics, Antitubercular; Aorta, Abdomina | 2011 |
[Retroperitoneal abscess in a patient under BCG treatment cause a bladder cancer].
Topics: Abdominal Abscess; Aged; Antitubercular Agents; BCG Vaccine; Humans; Isoniazid; Lung Neoplasms; Male | 2012 |
Association between carcinoma of the bladder and pulmonary tuberculosis: evaluation of PAS and INH as carcinogenic agents.
Topics: Aminosalicylic Acid; Carcinogens; Carcinoma; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonar | 1959 |
[Bilateral tuberculous epididymitis after intravesical Bacillus Calmette-Guerin therapy].
Topics: Administration, Intravesical; Aged; Antitubercular Agents; BCG Vaccine; Carcinoma, Transitional Cell | 2005 |
Granulomatous balanoposthitis after intravesical Bacillus-Calmette-Guerin instillation therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antitubercular Agents; Balanitis; BCG Vaccine; | 2006 |
Relationship of acetylator status to isoniazid toxicity, lupus erythematosus, and bladder cancer.
Topics: Acetylation; Acetyltransferases; Arylamine N-Acetyltransferase; Humans; Isoniazid; Liver; Lupus Eryt | 1983 |
Epidemiological studies of medically used drugs.
Topics: 2-Naphthylamine; Brain Neoplasms; Epidemiologic Methods; Female; Humans; Isoniazid; Liver Neoplasms; | 1980 |
N-acetylation phenotype in bladder cancer.
Topics: Acetylation; Aged; Carcinogens; Female; Half-Life; Humans; Isoniazid; Male; Middle Aged; Phenotype; | 1982 |
CYP1A2 activity as a risk factor for bladder cancer.
Topics: Acetylation; Adult; Aged; Amines; Carcinoma, Transitional Cell; Case-Control Studies; Cytochrome P-4 | 1994 |
Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.
Topics: Administration, Intravesical; Antibodies, Bacterial; Antibody Formation; Cell Count; Humans; Immunog | 1994 |
Polyarthritis in an elderly man with bladder cancer.
Topics: Administration, Intravesical; Aged; Arthritis; BCG Vaccine; Carcinoma, Transitional Cell; Drug Thera | 1994 |
N-acetyltransferase activity in the urine in Japanese subjects: comparison in healthy persons and bladder cancer patients.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Arylamine N-Acetyltransferase; Asian People | 1995 |
Effects of isoniazid on the proliferation and cytokine production of bladder cancer cells in vitro induced by bacille Calmette-Guérin.
Topics: Antitubercular Agents; BCG Vaccine; Cell Division; Humans; Immunotherapy; Interleukin-6; Interleukin | 1997 |
Acid-fast bacilli persisting in the genitourinary tract 3 years after intravesical bacille Calmette-Guérin therapy for bladder carcinoma.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antitubercular; Antitubercular Agents; BCG Vaccine; Carci | 1998 |
Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Amoxicillin; Antitubercular Agents; BCG Vacci | 1998 |
Acute mental changes in a 68-year-old man with bladder cancer.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Confusion; Hematuria; | 1998 |
Refractory arthropathy after intravesical bacillus Calmette-Guérin therapy. Usefulness of isoniazide.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antitubercular Agents; Arthritis; BCG Va | 1999 |
Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy.
Topics: Administration, Intravesical; Aged; Antitubercular Agents; BCG Vaccine; Drug Therapy, Combination; E | 1999 |
Relative importance of risk factors in bladder carcinogenesis.
Topics: Female; Humans; Isoniazid; Male; Risk; Sex Factors; Smoking; Urinary Bladder Neoplasms | 1978 |
Urinary tract cancer and isoniazid.
Topics: Female; Humans; Isoniazid; Kidney Neoplasms; Male; Maryland; Middle Aged; Tuberculosis, Pulmonary; U | 1977 |
Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig.
Topics: Administration, Intravesical; Animals; BCG Vaccine; Dinitrochlorobenzene; Female; Guinea Pigs; Histo | 1992 |
Systemic bacillus Calmette-Guérin infection, 'BCGitis', in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Humans; Isoniazid; Ma | 1989 |
[Acetylation phenotype in patients with cancer of the bladder. Preliminary report].
Topics: Acetylation; Acetyltransferases; Adult; Aged; Female; Genetic Markers; Humans; Isoniazid; Male; Midd | 1988 |
Differential susceptibility: implications for epidemiology, risk assessment, and public policy.
Topics: Acetylation; Animals; Benzidines; Carcinogens, Environmental; Genetic Predisposition to Disease; Gen | 1988 |
Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.
Topics: Biological Products; Combined Modality Therapy; Cycloserine; Female; Humans; Immunotherapy; Isoniazi | 1986 |
Tuberculosis chemotherapy and risk of bladder cancer.
Topics: Adult; Aged; Antitubercular Agents; Carcinoma; Female; Humans; Isoniazid; Male; Middle Aged; Risk; S | 1985 |
Tryptophan metabolism as affected by anovulatory agents.
Topics: Aminohippuric Acids; Chlorotrianisene; Diethylstilbestrol; Estrogens; Female; Humans; Isoniazid; Kyn | 1969 |
Letter: Isoniazid and cancer risks.
Topics: Animals; Child; Child, Preschool; Humans; Isoniazid; Male; Neoplasms; Tuberculosis; Urinary Bladder | 1974 |
Extrapolation of experimental carcinogenicity to the reality of industrial exposure.
Topics: Animals; Carbon Tetrachloride; Carcinogens; Chemical Industry; Cyclamates; Drug Contamination; Envir | 1972 |